Trial intelligence / Profile preview

DDI Study of Telotristat Etiprate and Midazolam in Healthy Subjects

NCT02147808Phase 1Completed

Sponsor
Lexicon Pharmaceuticals, Inc.
Start
May 2014
Primary completion
Aug 2014
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, open-label, single-arm trial of telotristat ethyl in Carcinoid Syndrome (CS), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoint: Midazolam plasma concentration in combination with steady state telotristat etiprate at Day 9. Started May 2014; status: completed.

02

Drugs

telotristat ethyl
03

Conditions

Carcinoid Syndrome (CS)

Beyond the preview

Go deeper on NCT02147808.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02147808.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call